EDGEWISE THERAPEUTICS INC (EWTX) — insider trading
Health Care · NASDAQ
EDGEWISE THERAPEUTICS INC (EWTX) has 23 reported SEC Form 4 insider transactions in our data, including 5 open-market sales among the most recent 23 (latest 2026-07-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 69,648 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 130,352 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Open-market sale | 69,648 | $39.41 | $2.74M | Form 4 |
| 2026-07-01 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Open-market sale | 130,352 | $39.41 | $5.14M | Form 4 |
| 2026-07-01 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Option exercise / conversion | 69,648 | $0.18 | $12.5K | Form 4 |
| 2026-07-01 | Russell Alan J | Director, Officer (Chief Scientific Officer) | Option exercise / conversion | 130,352 | $0.45 | $58.7K | Form 4 |
| 2026-07-01 | Fox Jonathan C | Director | Grant / award / vesting | 319 | $0.00 | $0 | Form 4 |
| 2026-06-05 | ROOT JONATHAN D | Director | Grant / award / vesting (derivative) | 16,377 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Morris Arlene | Director | Grant / award / vesting (derivative) | 16,377 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Thompson Peter A. | Director, 10% owner | Grant / award / vesting (derivative) | 16,377 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Brege Laura | Director | Grant / award / vesting (derivative) | 16,377 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Fox Jonathan C | Director | Grant / award / vesting (derivative) | 16,377 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Martin Christopher Nathan | Director | Grant / award / vesting (derivative) | 16,377 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Edris Badreddin | Director | Grant / award / vesting (derivative) | 8,188 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Edris Badreddin | Director | Grant / award / vesting (derivative) | 5,619 | $0.00 | $0 | Form 4 |
| 2026-05-05 | Donovan Joanne M. | Officer (CMO) | Option exercise / conversion (derivative) | 50,000 | $0.00 | $0 | Form 4 |
| 2026-05-05 | Donovan Joanne M. | Officer (CMO) | Open-market sale | 50,000 | $38.57 | $1.93M | Form 4 |
| 2026-05-05 | Donovan Joanne M. | Officer (CMO) | Option exercise / conversion | 50,000 | $7.08 | $354.0K | Form 4 |
| 2026-05-04 | Donovan Joanne M. | Officer (CMO) | Open-market sale | 5,230 | $31.29 | $163.7K | Form 4 |
| 2026-04-01 | Fox Jonathan C | Director | Grant / award / vesting | 339 | $0.00 | $0 | Form 4 |
| 2026-04-01 | Donovan Joanne M. | Officer (CMO) | Option exercise / conversion (derivative) | 28,662 | $0.00 | $0 | Form 4 |
| 2026-04-01 | Donovan Joanne M. | Officer (CMO) | Open-market sale | 28,662 | $32.31 | $926.1K | Form 4 |
| 2026-04-01 | Donovan Joanne M. | Officer (CMO) | Option exercise / conversion | 28,662 | $7.08 | $202.9K | Form 4 |
Ask the chat about EWTX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: EDGEWISE THERAPEUTICS INC (EWTX).
Last updated 2026-07-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.